PeptiDream Inc., a public Japan-based biopharmaceutical company (President: Patrick C. Reid, hereinafter "PeptiDream")(Tokyo: 4587), announced the achievement of a preclinical development milestone in ...

Construction at the Norton site is currently underway, with the new offerings anticipated to be operational by late 2027.

Following a Wednesday morning event at Alnylam Pharmaceuticals on Commerce Way, Gov. Maura Healey spoke with The Sun ...

With six drugs approved for commercial development, Cambridge-based drugmaker Alnylam Pharmaceuticals Inc. is investing $250 ...

With demand for its RNA interference meds booming, Alnylam Pharmaceuticals has commenced work to soup up its flagship ...

Alnylam is making a $250 million investment in its Massachusetts manufacturing facility. The investment comes as the company begins to expand beyond rare disease treatments into more common conditions ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the planned expansion of its state-of-the-art manufacturing facility in Norton, Massachusetts. The ...

The expansion will add about one-third more active manufacturing space to Alnylam's production facility in Norton, and it is ...

Norgine, a leading European specialty pharmaceutical company, today announced an exclusive licensing agreement under which ...

A technical analysis of Alnylam stock, explaining the recent correction, and what investors should expect next.

HELIOS-B is a global, randomized, double-blind, placebo-controlled clinical trial that evaluated the efficacy and safety of AMVUTTRA (R) in adult patients with wtATTR or hATTR amyloidosis with ...

The Nasdaq-100 Index has announced its annual reconstitution, with six new companies being added and six being removed, ...